Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
Viking Therapeutics is a relatively new entrant to the GLP1 space that has been building buzz for a while now:
Home - Viking Therapeutics
Novel therapeutics for metabolic and endocrine disorders.
It turns out the buzz was well deserved – the work they've been doing on a new GLP1 that they call VK2735 (Dual GLP-1/GIP agonist) was just presented at ObesityWeek and it was absolutely smashing hit.
The Phase 2 VENTURE study found that large doses of VK2735featured an 8% weight loss at 28 days.
Want to read our writeup and learn more about VK2735?
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
